ARID1A and neoplasm: However, these results do not discount the importance of developing therapeutic strategies to target tumours with loss of ARID1A and the clinical relevance of investigating the possible predictive value of ARID1A for immune‐modulatory therapies, given the overall poor clinical outcome in these disease types.